229 related articles for article (PubMed ID: 22352453)
21. Variable cytochrome P450 2D6 expression and metabolism of codeine and other opioid prodrugs: implications for the Australian anaesthetist.
Wilcox RA; Owen H
Anaesth Intensive Care; 2000 Dec; 28(6):611-9. PubMed ID: 11153286
[TBL] [Abstract][Full Text] [Related]
22. Physiologically-based pharmacokinetic modeling for mirabegron: a multi-elimination pathway mediated by cytochrome P450 3A4, uridine 5'-diphosphate-glucuronosyltransferase 2B7, and butyrylcholinesterase.
Konishi K; Minematsu T; Nagasaka Y; Tabata K
Xenobiotica; 2019 Aug; 49(8):912-921. PubMed ID: 30301385
[TBL] [Abstract][Full Text] [Related]
23. Same incidence of adverse drug events after codeine administration irrespective of the genetically determined differences in morphine formation.
Eckhardt K; Li S; Ammon S; Schänzle G; Mikus G; Eichelbaum M
Pain; 1998 May; 76(1-2):27-33. PubMed ID: 9696456
[TBL] [Abstract][Full Text] [Related]
24. Genetic predictors of the clinical response to opioid analgesics: clinical utility and future perspectives.
Lötsch J; Skarke C; Liefhold J; Geisslinger G
Clin Pharmacokinet; 2004; 43(14):983-1013. PubMed ID: 15530129
[TBL] [Abstract][Full Text] [Related]
25. CYP2D6 polymorphisms and codeine analgesia in postpartum pain management: a pilot study.
VanderVaart S; Berger H; Sistonen J; Madadi P; Matok I; Gijsen VM; de Wildt SN; Taddio A; Ross CJ; Carleton BC; Hayden MR; Koren G
Ther Drug Monit; 2011 Aug; 33(4):425-32. PubMed ID: 21743374
[TBL] [Abstract][Full Text] [Related]
26. Response to hydrocodone, codeine and oxycodone in a CYP2D6 poor metabolizer.
Susce MT; Murray-Carmichael E; de Leon J
Prog Neuropsychopharmacol Biol Psychiatry; 2006 Sep; 30(7):1356-8. PubMed ID: 16631290
[TBL] [Abstract][Full Text] [Related]
27. Application of Model Informed Precision Dosing to Address the Impact of Pregnancy Stage and CYP2D6 Phenotype on Foetal Morphine Exposure.
Badaoui S; Hopkins AM; Rodrigues AD; Miners JO; Sorich MJ; Rowland A
AAPS J; 2021 Jan; 23(1):15. PubMed ID: 33404848
[TBL] [Abstract][Full Text] [Related]
28. Pharmacogenetics of codeine metabolism in an urban population of children and its implications for analgesic reliability.
Williams DG; Patel A; Howard RF
Br J Anaesth; 2002 Dec; 89(6):839-45. PubMed ID: 12453926
[TBL] [Abstract][Full Text] [Related]
29. Microsomal codeine N-demethylation: cosegregation with cytochrome P4503A4 activity.
Caraco Y; Tateishi T; Guengerich FP; Wood AJ
Drug Metab Dispos; 1996 Jul; 24(7):761-4. PubMed ID: 8818573
[TBL] [Abstract][Full Text] [Related]
30. Urinary excretion of codeine, ethylmorphine, and their metabolites: relation to the CYP2D6 activity.
Hedenmalm K; Sundgren M; Granberg K; Spigset O; Dahlqvist R
Ther Drug Monit; 1997 Dec; 19(6):643-9. PubMed ID: 9421105
[TBL] [Abstract][Full Text] [Related]
31. Codeine and morphine in extensive and poor metabolizers of sparteine: pharmacokinetics, analgesic effect and side effects.
Poulsen L; Brøsen K; Arendt-Nielsen L; Gram LF; Elbaek K; Sindrup SH
Eur J Clin Pharmacol; 1996; 51(3-4):289-95. PubMed ID: 9010701
[TBL] [Abstract][Full Text] [Related]
32. A Compartmental Analysis for Morphine and Its Metabolites in Young Children After a Single Oral Dose.
Velez de Mendizabal N; Jimenez-Mendez R; Cooke E; Montgomery CJ; Dawes J; Rieder MJ; Aleksa K; Koren G; Jacobo-Cabral CO; Gonzalez-Ramirez R; Castañeda-Hernandez G; Carleton BC
Clin Pharmacokinet; 2015 Oct; 54(10):1083-90. PubMed ID: 25773480
[TBL] [Abstract][Full Text] [Related]
33. Functional phenotyping of the CYP2D6 probe drug codeine in the horse.
Gretler SR; Finno CJ; Kass PH; Knych HK
BMC Vet Res; 2021 Feb; 17(1):77. PubMed ID: 33581736
[TBL] [Abstract][Full Text] [Related]
34. Re: Apnea in a child after oral codeine: a genetic variant - an ultra-rapid metabolizer [corrected].
de Wildt SN; Koren G
Paediatr Anaesth; 2008 Mar; 18(3):273-4; author's reply 275-6. PubMed ID: 18230076
[No Abstract] [Full Text] [Related]
35. In vitro metabolism of the opioid tilidine and interaction of tilidine and nortilidine with CYP3A4, CYP2C19, and CYP2D6.
Weiss J; Sawa E; Riedel KD; Haefeli WE; Mikus G
Naunyn Schmiedebergs Arch Pharmacol; 2008 Sep; 378(3):275-82. PubMed ID: 18516595
[TBL] [Abstract][Full Text] [Related]
36. The effects of CYP2D6 and CYP3A activities on the pharmacokinetics of immediate release oxycodone.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):907-18. PubMed ID: 20590587
[TBL] [Abstract][Full Text] [Related]
37. Genetic polymorphisms and drug interactions modulating CYP2D6 and CYP3A activities have a major effect on oxycodone analgesic efficacy and safety.
Samer CF; Daali Y; Wagner M; Hopfgartner G; Eap CB; Rebsamen MC; Rossier MF; Hochstrasser D; Dayer P; Desmeules JA
Br J Pharmacol; 2010 Jun; 160(4):919-30. PubMed ID: 20590588
[TBL] [Abstract][Full Text] [Related]
38. A Single Site Population Study to Investigate CYP2D6 Phenotype of Patients with Persistent Non-Malignant Pain.
Radford H; Simpson KH; Rogerson S; Johnson MI
Medicina (Kaunas); 2019 May; 55(6):. PubMed ID: 31141989
[No Abstract] [Full Text] [Related]
39. Risk to the breast-fed neonate from codeine treatment to the mother: a quantitative mechanistic modeling study.
Willmann S; Edginton AN; Coboeken K; Ahr G; Lippert J
Clin Pharmacol Ther; 2009 Dec; 86(6):634-43. PubMed ID: 19710640
[TBL] [Abstract][Full Text] [Related]
40. A frameshift mutation and alternate splicing in human brain generate a functional form of the pseudogene cytochrome P4502D7 that demethylates codeine to morphine.
Pai HV; Kommaddi RP; Chinta SJ; Mori T; Boyd MR; Ravindranath V
J Biol Chem; 2004 Jun; 279(26):27383-9. PubMed ID: 15051713
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]